top bottom line forecast recent issu ep guidanc rais lower
tax rate guidanc reiter
ep estim consensu ep
guidanc increas vs first issu decemb
reflect lower tax rate guidanc unchang rais ep
estim ep estim review
sale forecast
consensu product ahead estim includ trulic cymbalta
zyprexa alimta effient humalog cyramza taltz combin
forecast product estim includ tradjenta light ciali
basaglar jardianc strattera portrazza olumi combin
light sale guidanc reiter last publish estim
gpm estim sg flat
estim ahead forecast net non-
op incom estim tax rate
forecast share count estim line item
guidanc unchang except tax rate lower approxim vs prior
verzenio abemaciclib approv mbc eu japan
approv mbc ph ii data combo w/herceptin mbc taltz
ph data axspa galcanezumab cgrp approv migrain prevent ph data
cluster headach lasmiditan file migrain treatment olumi baricitinib
approv ra fda adcom expect ph ii data sle initi ph alimta
label updat nsclc ph ii data non-sq nsclc w/keytruda
platinum patent rule ipr appeal ou rule germani japan cyramza ph
data liver cancer reach os intern data bladder cancer rang
intern data egfr nsclc relay jardianc initi ph ckd ph data
file fdc w/tradjenta metformin glucagon nasal regulatori file
hypoglycemia tanezumab w/pfe ph data oa pain clbp tradjenta data
cv outcom studi carmelina carolina intern readout trulic cv outcom
intern data rewind ultra-rapid insulin initi ph elanco decis statu post
strateg review provid earn call juli
pleas see page report import disclosur
number promis new drug rollout late-stag agent pois launch
next year give us confid top-tier sale ep growth prospect pipelin
visibl improv overal margin target appear achiev estim
ep compound-annual-growth-rate among best pharma dividend yield attract
baricitinib eu japan rollout
perform diabet busi
galcanezumab approv migrain
revenu growth leverag
ep growth
declin alimta
temper keytruda/chemo
one four less visibl pipelin
candid gener
alimta declin rapidli
margin expans plan delay
margin expans sooner greater
compani global biopharmaceut compani incorpor
indiana two main segment human pharmaceut product anim health
product lead product area diabet metabol diseas
oncolog among other lilli anim health busi oper elanco anim
divis develop manufactur market product food companion
cowen compani
good mm cowen
cowen compani www lilli com
cowen compani
cowen compani
cowen compani
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl diabet portfolio
success pipelin product especi ramucirumab dulaglutid success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend greater expect
competit diabet affect franchis macro factor lessen appeal
